Bharat Bio to begin paediatric trials of Covaxin

Bharat Bio to begin paediatric trials of Covaxin

Bharat Biotech will soon begin clinical trials of its COVID-19 vaccine Covaxin on kids aged 2 to18 years from June 1, the Hyderabad headquartered vaccine maker had announced.

The vaccine was developed in association with the Indian Council of Medical Research and the National Institute of Virology. The company has recently received approvals from the drug regulator to carry out paediatric trials of the vaccine.

Raches Ella, Bharat Bio’s head-business development and international advocacy, said that the vaccine maker has also initiated the process to obtain the approval of the World Health Organisation (WHO) for Covaxin and expects the approval soon.